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Antibiotic resistance is a growing problem in the medical field. One group of antibiotics 
which are widely used for the treatment of bacterial infections are aminoglycosides(AG). They 
are commonly used to treat infections such as tuberculosis and meningitis, thus understanding 
the biological basis of antibiotic promiscuity by AG-modifying and uncovering molecular details 
by which they select their ligands holds importance in both medicinal and scientific communities 
(Serpersu and Norris, 2013). Aminoglycosides exert their antibacterial effect by binding to the 
16S RNA of the 30S ribosome and interfering protein transcription in the bacteria and eventually 
causing cell death. Bacteria have developed different mechanisms for resistance, one such 
mechanism is the rise of aminoglycoside modifying enzymes. AG-modifying enzymes are a 
large family of proteins where each member modifies a unique hydroxyl or amino functional 
groups in different aminoglycosides (Serpersu and Norris, 2013). These enzymes modify 
aminoglycosides by transferring phosphate, acetyl or nucleotidyl functional groups from co-
factors such as MgATP or Acetyl-CoA. This modification reduces the affinity of the 
aminoglycoside to the bacterial ribosome rendering it ineffective. The aminoglycoside N3-
acetyltransferase-IIIb (AAC-IIIb) is an antibiotic resistance enzyme which catalyzes an 
acetylation reaction which involves transferring an acetyl group from an acetyl-CoA to an amine 
in the C3 position in all aminoglycosides. AAC-IIIb is one of the most promiscuous AG-
modifying enzymes. It has a wide range of substrates. In a study by Norris et al., (2010), steady 
state kinetic analysis revealed that tobramycin, kanamycin A, kanamycin B, sisomycin, 
neomycin B, paromomycin, ribostamycin and lividomycin are all substrates with measurable 
rates. In this study, we analyzed AAC-IIIb peptides generated by trypsin digestion. Trypsin is a 
protease which cleaves proteins at Arginine and Lysine residues. Following trypsin digestion, the 
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sample is run through a high-performance liquid chromatography (HPLC) column to determine 
cleavage pattern and to separate tryptic peptides. Trypsin digestion was performed on the 
enzyme in its apo- and ligand-bound state to determine the structural changes that occur in the 
enzyme when the antibody is bound. The ligand in this case was neomycin which is one of the 
substrates for AAC-IIIb. The chromatograms from the two states indicate that there are ligand 
binding causes some structural changes in AAC-IIIb.   
 
 
Figure 1: Structure of Neomycin. Neomycin was the ligand used in this study. 
 
 
Figure 2: Homology-derived structure of AAC-IIIb 





The material for the study included AAC-IIIb, trypsin solution, neomycin, acetonitrile and 
trifluoroacetic acid (TFA). The AAC-IIIb used for this experiment was over-expressed and 
purified from Escherichia coli BL21(DE3) cells by Adrianne Norris and Sharin Raval. For the 
first few experiments we used a 100 µM of AAC-IIIb which was in 50 mM MOPS pH 7.5. Fresh 
trypsin solution was prepared daily for each experiment by dissolving lyophilized trypsin powder 
in 0.01M HCL to a final concentration of 200 µM. 1 µL of the trypsin solution was added to a 
100 µL of the enzyme solution. The final trypsin-to-enzyme ratio was 1:50. After the digestion 
had run for 10 minutes, we added 1 µl of 10% TFA to a final concentration of  0.01% to stop the 
reaction. The sample was then injected into the HPLC column and fragments were collected.   
 
Ligand bound solution: 
Neomycin bound enzyme was prepared by adding 0.4 µL of 502 µM de-sulfated neomycin to 
100 µL of 100 µM AAC-IIIb. This solution was allowed to equilibrate for 5 minutes. Then 1 µL 
of trypsin solution was added to the ligand bound enzyme and allowed to react for 10 minutes. 
Trypsin-to-enzyme ratio was kept at 1:50 to match it with the treatment of the apo-enzyme. TFA 
was added to a final concentration of 0.01% to stop the reaction. The sample was then injected 
into the HPLC column and fragments were collected. 
 
HPLC preparation and collection: 
The stationary phase of the column was C-18 bound Silica. We used two solutions for the mobile 
phase of the HPLC. Solution A is the aqueous solution which contained 0.1% TFA dissolved in 
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water. Solution B was the nonpolar solution which contained 0.1% TFA dissolved in acetonitrile. 
Prior to the application of the sample solution, the column was calibrated using a series of steps. 
First, we ran 50% of each solution for about 10 minutes. After that we ran 100% of solution B 
through the column for 10 minutes. Then the ratio was changed to 2% solution B and 98% 
solution A for 20 minutes. This was the ratio used at the start of the run. Throughout the run, the 
ratio of solution A and B was reversed so that at the end of the run the final solution was 2% of 
solution A and 98% of solution B. Thus, the mobile phase became more nonpolar as we 
continued through the run. Signal detection was at 280nm and 214nm. Each time there was a 
peak, fragments were collected. The total run time was 65 minutes. 
 
RESULTS: 
 High-performance liquid chromatography (HPLC) separates the peptides by size and 
hydrophobicity. Since the mobile phase is the non-polar acetonitrile, small hydrophilic peptides 
are eluted first; while long hydrophobic peptides have a longer retention time and are eluted 
later. The chromatogram of each run represents each peak that was recorded during the run. 
Below are the chromatograms for the peaks at 280nm. The chromatograms at 214nm are not 
shown here. Figure 3 represents the chromatogram of the apo-enzyme and figure 4 is the 
chromatogram of the neomycin-bound enzyme. From the apo-enzyme, 17 peptides were 
collected and 12 were collected from the ligand bound enzyme. Most of the peaks from the apo-
enzyme have corresponding peaks in the ligand bound form. One of the peptides of interest is the 
last peptide that was recorded in the apo-enzyme. In the ligand bound form, it appears that this 
peptide is divided into two peptides due to the presence of two peaks where there was only one 
in the apo-enzyme. From the results, we suspect that a lysine or an arginine in that peptide was 
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exposed during ligand binding, allowing access to cleavage by trypsin. We attempted to analyze 
these fragments further using NMR, however the sample concentrations were too low for a 
meaningful data acquisition. In the future, we hope that increasing the concentration of the 
enzyme used can help us get a better result from NMR. 
 
Figure 3: Chromatogram of apo-enzyme at 280nm 
 
 
Figure 4: Chromatogram of the enzyme-ligand complex at 280nm 
 
DISCUSSION: 
 Studies on the structure of AAC-IIIb have found that the enzyme has a rigid structure in 
its apo- and ligand-bound forms except for a flexible loop that is found near the AG binding site. 
This loop is comprised of ~35 amino acids. Examining the differences in the chromatograms of 
the apo and ligand bound AAC-IIIb can help us potentially determine parts of the protein that 
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changes exposure to solvent upon ligand binding, which awaits determination of peptide 
sequences by NMR. 
 The chromatograms show that the peaks are concentrated around the same area in both 
samples. However, the apo-enzyme and ligand bound enzyme differ in the number of peptides 
they produce during tryptic digestion. From the apo-enzyme 17 peptides were collected, while 
only 12 peptides were collected from the tryptic digestion of the enzyme-ligand complex. This 
suggests that ligand binding hides some of the Lysine and Arginine residues reducing the 
cleavage sites. Additionally, in the peptides that appeared comparable in the apo- and ligand- 
states that was a slight shift in the retention times. For example, the  peptide that appeared at 
22.15 in the apo-state, was collected at 24.85 in the ligand-bound state. This suggests that ligand 
binding exposes different amino acids shifting the hydrophobicity of the peptide. These 
differences in the chromatography profiles suggest that aminoglycoside binding causes   
conformational changes in AAC-IIIb. 
 We examined the amino acid sequence of AAC-IIIb to give us an idea of the possible 
peptides that are generated by trypsin digestion. Below is the amino acid sequence for AAC-IIIb 
grown in E. coli BL21(DE3) cells. The possible cleavage sites are highlighted in yellow (lysine) 
and green (arginine). Hydrophobic side chains, tryptophan (W) and tyrosine (Y), with an 
absorbance of 280nm are also highlighted. Peptides without tryptophan or tyrosine are not 
represented in the above chromatograms which show the peaks at 280nm.   
 
MTSATASFAT   RTSLAADLAA   LGLAWGDAIM   VHAAVSRVGR   LLDGPDTIIA 
ALRDTVGPGG   TVLAYADWEA   RYEDLVDDAG   RVPPEWREHV   PPFDPQRSRA 
IRDNGVLPEF   LRTTPGTLRS   GNPGASLVAL   GAKAEWFTAD   HPLDYGYGEG 
SPLAKLVEAG   GKVLMLGAPL   DTLTLLHHAE   HLADIPGKRI   KRIEVPFATP 
TGTQWRMIEE   FDTGDPIVAG   LAEDYFAGIV   TEFLASGQGR   QGLIGAAPSV 




Figure 5: Possible trypsin cleavage sites for AAC-IIIb. Lysine(K) and Arginine(R) which are 
amino acids recognized and cleaved by trypsin are highlighted. Tryptophan(W) and Tyrosine(Y) 
are highlighted in grey since those are the amino acids with an absorbance of 280nm.  
  
Potential amino acid sequence of the peptide at which there is some structural change: 
 
 IEVPFATP TGTQWRMIEE   FDTGDPIVAG   LAEDYFAGIV   TEFLASGQG 
 
 
We propose that  the peptide shown above may be the one that elutes at 36.07 in the apo-
enzyme. Since this peptide is hydrophobic due to the presence of a number of phenylalanine 
residues,, we expect that it would have a longer retention time than other peptides. In the apo-
enzyme we propose that the arginine in the middle of this peptide is hidden and it elutes as one 
peptide. In the ligand-bound enzyme, on the other hand, this arginine is exposed and available 
for cleavage by trypsin. Thus, this peptide is cleaved and elutes as two smaller peptides. This 
hypothesis can be tested further using NMR analysis of these samples.  
 Figure 6: Structure of AAC-IIIb. The peptide 
shown above is highlighted yellow and the arginine is highlighted red. The loop involved in 
ligand binding is highlighted in green. 
This structure of AAC-IIIb supports our data. In the apo-enzyme, the flexible loop shields 
the highlighted arginine from cleavage by trypsin. Therefore, the peptide highlighted in yellow 
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elutes as one long peptide. However, when neomycin is bound the loop folds around the ligand 
exposing this arginine to cleavage. This suggests that ligand binding causes structural changes in 
AAC-IIIb.   
CONCLUSION: 
 Structural analysis of aminoglycoside-modifying enzymes has significance in scientific 
and medical communities. Understanding protein-ligand interactions will help us design 
antibiotics that are resistant to the action of AG-modifying enzymes such as AAC-IIIb. With the 
rise of strains of multidrug-resistant Tuberculosis, it is becoming more important to design novel 
antibiotics which can combat bacterial growth and are not susceptible to modification by 
resistance conferring bacterial enzymes. The present study investigates the protein-enzyme 
interaction between AAC-IIIb and neomycin by comparing trypsin digestion patterns in the apo- 
and ligand-bound state of the enzyme. To further investigate protein-ligand interactions, more 
experiments analyzing conformational changes in AAC-IIIb can be done using ligands which are 
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